Correlation Between Procaps Group and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Procaps Group and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Procaps Group and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Procaps Group SA and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Procaps Group and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Procaps Group with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Procaps Group and Supernus Pharmaceuticals.

Diversification Opportunities for Procaps Group and Supernus Pharmaceuticals

-0.16

Correlation Coefficient

Procaps Group  Supernus Pharmaceuticals

Good diversification

The 3 months correlation between Procaps and Supernus is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Procaps Group SA and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Procaps Group is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Procaps Group SA are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Procaps Group i.e., Procaps Group and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Procaps Group and Supernus Pharmaceuticals

Given the investment horizon of 90 days Procaps Group SA is expected to under-perform the Supernus Pharmaceuticals. In addition to that, Procaps Group is 9.42 times more volatile than Supernus Pharmaceuticals. It trades about -0.01 of its total potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about 0.05 per unit of volatility. If you would invest  3,668  in Supernus Pharmaceuticals on October 9, 2024 and sell it today you would earn a total of  37.00  from holding Supernus Pharmaceuticals or generate 1.01% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Procaps Group SA  vs.  Supernus Pharmaceuticals

Procaps Group SA

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Procaps Group SA are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Procaps Group exhibited solid returns over the last few months and may actually be approaching a breakup point.

Supernus Pharmaceuticals

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Procaps Group and Supernus Pharmaceuticals

The main advantage of trading using opposite Procaps Group and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Procaps Group position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Procaps Group SA and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.